DENGVAXIA, the first vaccine approved by Sanofi Pasteur for the prevention of dengue, is now being administered by healthcare providers in the Philippines.
The healthcare providers receive the first shipment of the vaccine earlier this month.
The vaccine is administered in three doses over one year.
“This is truly a great moment in the history of vaccinology,” said Guillaume Leroy, vice president of Dengue Vaccine, Sanofi Pasteur.
Approved in the Philippines last December, Dengvaxia prevents disease caused by all four dengue types in individuals from 9-45 years of age living in endemic areas.
The vaccine has also been approved in Mexico, Brazil and El Salvador.